Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

An effective therapy for human adenovirus (HAdV) infections in immunocompromised patients and healthy individuals with community-acquired pneumonia remains an unmet medical need. We herein reported a series of novel substituted N-(4-amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide analogues as potent HAdV inhibitors. Compounds 6, 15, 29, 40, 43, 46, 47, and 54 exhibited increased selectivity indexes (SI > 100) compared to the lead compound niclosamide, while maintaining sub-micromolar to low micromolar potency against HAdV. The preliminary mechanistic studies indicated that compounds 6 and 43 possibly target the HAdV DNA replication process, while compounds 46 and 47 suppress later steps of HAdV life cycle. Notably, among these derivatives, compound 15 showed improved anti-HAdV activity (IC50 = 0.27 μM), significantly decreased cytotoxicity (CC50 = 156.8 μM), and low in vivo toxicity (maximum tolerated dose = 150 mg/kg in hamster) as compared with niclosamide, supporting its further in vivo efficacy studies for the treatment of HAdV infections.


Jimin Xu, Judith Berastegui-Cabrera, Na Ye, Marta Carretero-Ledesma, Jerónimo Pachón-Díaz, Haiying Chen, Maria Eugenia Pachón-Ibáñez, Javier Sánchez-Céspedes, Jia Zhou. Discovery of Novel Substituted N-(4-Amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide Analogues as Potent Human Adenovirus Inhibitors. Journal of medicinal chemistry. 2020 Nov 12;63(21):12830-12852

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 33112138

View Full Text